These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27281790)

  • 21. HIV Treatment and Prevention: A Simple Model to Determine Optimal Investment.
    Juusola JL; Brandeau ML
    Med Decis Making; 2016 Apr; 36(3):391-409. PubMed ID: 26369347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis.
    Ward Z; Stone J; Bishop C; Ivakin V; Eritsyan K; Deryabina A; Low A; Cepeda J; Kelly SL; Heimer R; Cook R; Altice FL; Litz T; Terlikbayeva A; El-Bassel N; Havarkov D; Fisenka A; Boshnakova A; Klepikov A; Saliuk T; Deshko T; Vickerman P
    Lancet HIV; 2022 Jan; 9(1):e42-e53. PubMed ID: 34895484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-level impact of an accelerated HIV response plan to reach the UNAIDS 90-90-90 target in Côte d'Ivoire: Insights from mathematical modeling.
    Maheu-Giroux M; Vesga JF; Diabaté S; Alary M; Baral S; Diouf D; Abo K; Boily MC
    PLoS Med; 2017 Jun; 14(6):e1002321. PubMed ID: 28617810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determining a cost effective intervention response to HIV/AIDS in Peru.
    Aldridge RW; Iglesias D; Cáceres CF; Miranda JJ
    BMC Public Health; 2009 Sep; 9():352. PubMed ID: 19765304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kazakhstan can achieve ambitious HIV targets despite expected donor withdrawal by combining improved ART procurement mechanisms with allocative and implementation efficiencies.
    Shattock AJ; Benedikt C; Bokazhanova A; Đurić P; Petrenko I; Ganina L; Kelly SL; Stuart RM; Kerr CC; Vinichenko T; Zhang S; Hamelmann C; Manova M; Masaki E; Wilson DP; Gray RT
    PLoS One; 2017; 12(2):e0169530. PubMed ID: 28207809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.
    Dutta A; Barker C; Kallarakal A
    PLoS Med; 2015 Nov; 12(11):e1001907; discussion e1001907. PubMed ID: 26599990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Global Fund's resource allocation decisions for HIV programmes: addressing those in need.
    Avdeeva O; Lazarus JV; Aziz MA; Atun R
    J Int AIDS Soc; 2011 Oct; 14():51. PubMed ID: 22029667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How should HIV resources be allocated? Lessons learnt from applying Optima HIV in 23 countries.
    Stuart RM; Grobicki L; Haghparast-Bidgoli H; Panovska-Griffiths J; Skordis J; Keiser O; Estill J; Baranczuk Z; Kelly SL; Reporter I; Kedziora DJ; Shattock AJ; Petravic J; Hussain SA; Grantham KL; Gray RT; Yap XF; Martin-Hughes R; Benedikt CJ; Fraser-Hurt N; Masaki E; Wilson DJ; Gorgens M; Mziray E; Cheikh N; Shubber Z; Kerr CC; Wilson DP
    J Int AIDS Soc; 2018 Apr; 21(4):e25097. PubMed ID: 29652100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Access to antiretroviral therapy and survival in eastern Europe and central Asia: a case study in Armenia.
    Mallitt KA; Grigoryan SR; Papoyan AS; Wand HC; Wilson DP
    J Int AIDS Soc; 2014; 17(1):18795. PubMed ID: 25095830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optima: A Model for HIV Epidemic Analysis, Program Prioritization, and Resource Optimization.
    Kerr CC; Stuart RM; Gray RT; Shattock AJ; Fraser-Hurt N; Benedikt C; Haacker M; Berdnikov M; Mahmood AM; Jaber SA; Gorgens M; Wilson DP
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):365-76. PubMed ID: 25803164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact and Cost of Scaling Up Voluntary Medical Male Circumcision for HIV Prevention in the Context of the New 90-90-90 HIV Treatment Targets.
    Kripke K; Reed J; Hankins C; Smiley G; Laube C; Njeuhmeli E
    PLoS One; 2016; 11(10):e0155734. PubMed ID: 27783681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Employing resource allocation modeling to inform HIV prevention planning for the state of Iowa.
    Holtgrave DR; Young PA; Mayer RR; Maulsby C; Kim JJ
    AIDS Educ Prev; 2013 Oct; 25(5):423-9. PubMed ID: 24059879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in HIV prevention programme outcomes among key populations in Kenya: Data from periodic surveys.
    Musyoki H; Bhattacharjee P; Blanchard AK; Kioko J; Kaosa S; Anthony J; Javalkar P; Musimbi J; Malaba SJ; Olwande C; Blanchard JF; Sirengo M; Isac S; Moses S
    PLoS One; 2018; 13(9):e0203784. PubMed ID: 30231072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost-effectiveness of harm reduction.
    Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.
    Gomez GB; Borquez A; Case KK; Wheelock A; Vassall A; Hankins C
    PLoS Med; 2013; 10(3):e1001401. PubMed ID: 23554579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact and cost-effectiveness of the national scale-up of HIV pre-exposure prophylaxis among female sex workers in South Africa: a modelling analysis.
    Stone J; Bothma R; Gomez GB; Eakle R; Mukandavire C; Subedar H; Fraser H; Boily MC; Schwartz S; Coetzee J; Otwombe K; Milovanovic M; Baral S; Johnson LF; Venter WDF; Rees H; Vickerman P
    J Int AIDS Soc; 2023 Feb; 26(2):e26063. PubMed ID: 36807874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.
    Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L
    Lancet Glob Health; 2017 Dec; 5(12):e1208-e1220. PubMed ID: 29074410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of combination prevention strategies on HIV incidence among gay and bisexual men who have sex with men in the UK: a model-based analysis.
    Cambiano V; Miners A; Lampe FC; McCormack S; Gill ON; Hart G; Fenton KA; Cairns G; Thompson M; Delpech V; Rodger AJ; Phillips AN
    Lancet HIV; 2023 Nov; 10(11):e713-e722. PubMed ID: 37923485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV incidence among people who inject drugs in the Middle East and North Africa: mathematical modelling analysis.
    Mumtaz GR; Awad SF; Feizzadeh A; Weiss HA; Abu-Raddad LJ
    J Int AIDS Soc; 2018 Mar; 21(3):e25102. PubMed ID: 29577623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries.
    Degenhardt L; Mathers BM; Wirtz AL; Wolfe D; Kamarulzaman A; Carrieri MP; Strathdee SA; Malinowska-Sempruch K; Kazatchkine M; Beyrer C
    Int J Drug Policy; 2014 Jan; 25(1):53-60. PubMed ID: 24113623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.